Parathyroid Hormone
Approved · EMAAlso known as Natpara, PTH, PTH - Parathyroid hormone, PTH(1-84)+4 more
Natpara, PTH, PTH - Parathyroid hormone, PTH(1-84), Parathormone, Parathyrin, Parathyroid hormone (1-84) human recombinant, Parathyroid hormone (rDNA).
Recent clinical, regulatory, research and industry developments relating to this drug.
Market withdrawal: Natpar (EMA)
Role of Parathyroid Hormone and Parathyroid Hormone-Related Protein in Protein-Energy Malnutrition.
Comparison of 3 Month PTHrP(1-36) and PTH(1-34) on Post-Menopausal Osteoporosis
Bone Properties in Hypoparathyroidism: Effects of PTH
Can Risedronate and Parathyroid Hormone Reverse Glucocorticoid Induced Osteoporosis?
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
Evidence ↗Indication: Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
Evidence ↗Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Bone Properties in Hypoparathyroidism: Effects of PTH
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes4
Journals, researchers & institutions
- European journal of endocrinology1
- Frontiers in bioscience (Landmark edition)1
- Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA1
- Pediatric nephrology (Berlin, Germany)1
- The Journal of clinical endocrinology and metabolism1
- The Journal of clinical investigation1
- Black DM2
- Palermo L2
- Schafer AL2
- Sellmeyer DE2
- Shoback DM2
- Bakkaloglu S1
- Bollerslev J1
- Buch O1
- Aarhus University Hospital1
- and Institute for Research and Innovation in Health of the University of Porto1
- Aristotle University1
- Brigham and Women's Hospital and Harvard Medical School1
- Centre de Recherche des Cordeliers1
- Centre de Référence des Maladies Rares du Calcium et du Phosphate1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across the same disease area as Parathyroid Hormone in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.